Last reviewed · How we verify
NCT07234032
An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Phase 3 trial testing Treprostinil Palmitil Inhalation Powder in Pulmonary Hypertension in 344 participants. Not yet recruiting.
22 January 2031
Quick facts
| Lead sponsor | Insmed Incorporated |
|---|---|
| Phase | Phase 3 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 344 |
| Start date | 1 April 2026 |
| Primary completion | 22 January 2031 |
| Estimated completion | 22 January 2031 |
Drugs / interventions tested
- Treprostinil Palmitil Inhalation Powder — full drug profile →
- Placebo
Conditions studied
- Pulmonary Hypertension — all drugs for Pulmonary Hypertension →
- Interstitial Lung Disease — all drugs for Interstitial Lung Disease →
Sponsor
Insmed Incorporated — full company profile →
Who can join
18 and older, any sex, with Pulmonary Hypertension or Interstitial Lung Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary objective of this study is to evaluate the safety and tolerability of the long-term use of TPIP in participants with PH-ILD from Study INS1009-311 (NCT07179380).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07234032
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Treprostinil Palmitil Inhalation Powder
Trials testing the same drug.
- NCT07481981 — A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants · Phase 3 · not yet recruiting
- NCT07179380 — Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension · Phase 3 · recruiting
- NCT05649722 — An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Hypertension Associated With Intersti · Phase 2, PHASE3 · active not recruiting
- NCT06091579 — A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder (TPIP) in H · Phase 1 · completed
Other recruiting trials for Pulmonary Hypertension
Currently open trials in the same condition.
- NCT07179380 — Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension · Phase 3 · recruiting
- NCT07073820 — A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have P · Phase 2 · recruiting
- NCT06351345 — 129 Xenon Imaging in Patients Treated With Sotatercept · Phase 2 · recruiting
- NCT07187206 — Safety and Efficacy of FETO in CDH Phase III · Phase 3 · recruiting
- NCT07206173 — Londrina Activities of Daily Living Protocol in Pulmonary Hypertension · recruiting
Other Insmed Incorporated trials
Trials by the same sponsor.
- NCT07481981 — A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants · Phase 3 · not yet recruiting
- NCT07179380 — Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension · Phase 3 · recruiting
- NCT07102316 — A Study to Assess the Relative Bioavailability After a Single Inhalation Administration of Treprostinil Palmitil Inhalat · Phase 1 · completed
- NCT06685835 — A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS) · Phase 2 · active not recruiting
- NCT06344728 — A Study to Assess the Relative Bioavailability of Brensocatib Pediatric Oral Solution to Oral Tablets in Healthy Partici · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07234032 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Insmed Incorporated
- Last refreshed: 18 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07234032.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing